1 Min Read
May 21 (Reuters) - Intrexon Corp:
* PRECIGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL STUDY OF INXN-4001 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.